Breaking News

Zenith Licenses Kinex Programs

May 6, 2013

Will commit resources to global Oraxol, Oratecan

Kinex Pharmaceuticals and Zenith Technology Corp., through its affiliate ZenRx, have entered a collaborative licensing agreement granting Zenith commercial rights to Oraxol and Oratecan in New Zealand and Australia. ZenRx will provide an undisclosed upfront payment, milestones and royalties. Zenith will commit significant resources to the Oraxol and Oratecan global development programs, providing Kinex and its partner, Hanmi Pharmaceuticals with additional clinical programs to support global registrations.
 
The Orascovery technology has led to trials being conducted with both an oral formulation of paclitaxel (Oraxol), currently in Phase II in Korea, and an oral formulation of Irinotecan (Oratecan), which has completed a Phase I trial in Korea. Additional trials are being planned in both Korea and the U.S.
 
Johnson Lau, chief executive officer of Kinex Pharmaceuticals, said, "The commitment of Zenith Technology to work closely with Kinex and our partner Hanmi Pharmaceuticals in the development of Oraxol and Oratecan is a critical element of our global development strategy. We are very pleased to be working with the experienced Zenith team to move our clinical programs to the next stage."

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent